Panelists discuss the evolving management of metastatic breast cancer with CDK4/6 inhibitors—highlighting long-term safety, emerging clinical data, sequencing strategies, multidisciplinary care, and the growing use of digital and precision tools to enhance adherence, optimize outcomes, and individualize treatment across diverse patient populations.
Panelists discuss how pharmacists play a crucial role in optimizing CDK4/6 inhibitor therapy for patients with breast cancer through patient identification, toxicity management, adherence support, and multidisciplinary care coordination across both early-stage and metastatic treatment settings.
Panelists discuss how understanding the clinical characteristics and burden of tardive dyskinesia—especially in older adults—can inform the use of VMAT2 inhibitors, highlight ongoing care gaps, and underscore the vital role of pharmacists in optimizing therapeutic strategies and patient outcomes.
Panelists discuss best practices for maximizing respiratory syncytial virus (RSV) vaccine uptake in high-risk patients, comparing FDA-approved vaccines and emphasizing the pharmacist’s critical role in addressing hesitancy and improving access to protect vulnerable populations.
Panelists discuss how recent shifts in treatment patterns and real-world data on low-density lipoprotein cholesterol (LDL-C)–lowering therapies beyond statins can inform clinical decisions and improve outcomes for patients at very high risk post atherosclerotic cardiovascular disease (ASCVD), with an emphasis on the role of pharmacists in enhancing cholesterol management through shared decision-making.
Panelists discuss, current operational strategies and best practices for the implementation of bispecific antibody therapies, strategies for managing adverse effects associated with bispecific antibody therapies in multiple myeloma, opportunities for delivering bispecific antibody therapies for multiple myeloma in community healthcare settings, addressing challenges related to initial implementation, patient monitoring, and coordination with tertiary care centers.
Medical experts provide a comprehensive overview of pneumococcal disease in adults, discussing high-risk populations, vaccination strategies, recent vaccine developments, and current challenges, while emphasizing the importance of immunization and patient education in preventing severe outcomes and improving public health.
A panel of clinical pharmacists have a comprehensive discussion on optimizing cholesterol management in very high-risk patients with ASCVD.
A panel of experts highlights the importance of pharmacist involvement in prevention measures to combat respiratory syncytial virus (RSV) in adults.
Ryan Haumschild, PharmD, MS, MBA, leads a panel of experts in a discussion focusing on metastatic breast cancer (mBC) and early breast cancer (eBC), covering the most recent treatment guidelines, drug toxicities, and a comparative analysis of CDK4/6 inhibitors.
Expert pharmacists in myelofibrosis care share insights on emerging therapies, challenges, and their crucial role in patient advocacy and collaborative care team efforts in a comprehensive discussion.
Ryan Haumschild, PharmD, MS, MBA, leads a panel of experts in a discussion surrounding updates in CDK4/6 inhibitor use for patients with HR+/HER2- metastatic breast cancer.
A panel of experts discuss several topics pertaining to the importance of annual influenza immunizations, including the different available vaccine formulations, the ACIP recommendations, and addressing barriers related to immunizing populations yearly.
A panel of medical experts explore strategies to maximize RSV vaccination efforts in the adult patient population.
Ryan Haumschild, PharmD, MS, MBA leads a panel of medical experts in a discussion surrounding the significance of adult pneumococcal vaccination.
Experts discuss gut microbiota, current and emerging microbiome-based therapies for C difficile, and the practical ways to incorporate these treatments into your clinical practice.
Ryan Haumschild, PharmD, MS, MBA, leads a discussion surrounding relapsed/refractory multiple myeloma (MM).
Key opinion leaders discuss the disease state, treatment landscape, and future considerations for treating patients with myelodysplastic syndrome (MDS).
Expert health professionals provide key insights on recently approved SARS-CoV-2 booster shots highlighting current recommendations and optimizing patient communication and education on vaccination options.
Dr. Feuerstadt, a gastroenterologist, discusses foundational trials and ongoing studies in the use of fecal microbial transplantation (FMT) for treatment of recurrent C. difficile infections.
A panel of medical experts discuss treating acute myeloid leukemia (AML), from diagnosis to the different therapies available that give patients the best chance at survival.
Expert panelists provide insight on the relationship between the gut microbiome and c difficile, leading to the development of novel therapeutic approaches for infection.
In this Pharmacy Times Peer Exchange, a panel of pharmacists discuss treatment options for patients with atopic dermatitis, from systemic agents to topical agents, including the new developments occurring with JAK inhibitors.
A panel of key opinion leaders in cardiology and pharmacy provides a lively discussion on currently available and emerging therapeutic approaches for the treatment of heart failure.
What pharmacists need to know about managing patients who are prescribed more recent acute and preventive treatment options approved for migraine.
